{
  "id": 1692175,
  "title": "William Blair initiates Enliven Therapeutics stock with outperform rating",
  "url": "https://urgent.news/2026/08/18/william-blair-initiates-enliven-therapeutics-stock-with-outperform",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T10:52:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/william-blair-initiates-enliven-therapeutics-stock-with-outperform-rating-93CH-4864803"
  },
  "original_language": "en",
  "account": null,
  "summary": "William Blair initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an outperform rating, noting the chronic myeloid leukemia market is expanding and requires more effective, tolerable, and convenient treatment options. The stock has surged 287% year-to-date, trading near its 52-week high, though it appears overvalued at current levels. Analysts estimate the total addressable market for CML to be roughly $8.8 billion, including $5.6 billion from the United States. Enliven Therapeutics has completed a significant public offering, raising approximately $460 million in gross proceeds, while other analysts such as Barclays, Guggenheim, H.C. Wainwright, and Jones Trading have also provided coverage with varying ratings and price targets.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}